COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or post-exposure prophylactic COVID...

Full description

Bibliographic Details
Main Authors: Robert W. Malone, Philip Tisdall, Philip Fremont-Smith, Yongfeng Liu, Xi-Ping Huang, Kris M. White, Lisa Miorin, Elena Moreno, Assaf Alon, Elise Delaforge, Christopher D. Hennecker, Guanyu Wang, Joshua Pottel, Robert V. Blair, Chad J. Roy, Nora Smith, Julie M. Hall, Kevin M Tomera, Gideon Shapiro, Anthony Mittermaier, Andrew C. Kruse, Adolfo García-Sastre, Bryan L. Roth, Jill Glasspool-Malone, Darrell O. Ricke
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
famotidine (PubChem CID: 3325)
mast cell activating disorder
COVID-19
hyperinflammation state
GPCR (G Protein Coupled Receptors)
histamine (H2) receptor
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.633680/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.633680/full

Similar Items